GoggleDocs (@GoggleDocs) / X

GoggleDocs

2,747 posts

GoggleDocs

@GoggleDocs

🥽🩺Docs/nurses/pharmacists from U.K. Talking CardioRenoMetabolic & more Catch us on YouTube youtube.com/c/GoggleDocs |Educate, Motivate, Activate!

London, England

Joined October 2020

GoggleDocs
@GoggleDocs
Jun 25, 2024
Once monthly #semaglutide anyone? 🔹P1674 #ADA2024 🔸Novel injectable hydrogel vehicle under development by @Adocia_Biotech 🇫🇷 🔹data from 🐁 studies 👉 Still in pre-clinical. So years away, but fascinating❗️ @kamleshkhunti @PNewlandJones @Dralbalawi1989 @BevTchangMD
218K
GoggleDocs
@GoggleDocs
Oct 21, 2023
👉check out our 2 minute summary 🔗 youtu.be/5EUHJDRxczs #semaglutide #Ozempic #Wegovy #Rybelsus #type2diabetes #WeightLoss #MedTwitter @kamleshkhunti @AbdTahrani @Dralbalawi1989
345K
GoggleDocs
@GoggleDocs
Jul 27, 2023
Q. Do Artificial sweeteners (AS) ⤴️ #type2diabetes ❓ 🔹Cohort study (n=105,588) ⤴️AS intake associated with ⤴️ T2DM risk (HR 1.69; 95% CI 1.45–1.97;P<0.001) ‼️ ⚠️ Risk of reverse causality A. Probably 🔗diabetesjournals.org/care/article/d… @Dralbalawi1989 @kamleshkhunti @felly500
512K
GoggleDocs
@GoggleDocs
Jul 4, 2023
Does a #lowcarb solution reduce #HealthInequity in #type2diabetes ❓ 🔹random sample from @virtahealth🇺🇸telemedicine clinic presented at #ADA2023 ⚠️ no control group ⤵️Insulin & SU treatments - all groups ⤵️HbA1c- all groups ⤵️ diabetes medication - all groups
508K
GoggleDocs
@GoggleDocs
Nov 7, 2023
How does adding Tirzepatide compare with prandial insulin in #T2D using Basal insulin❓ (SURPASS-6) 🔹 HbA1c ⤵️ 2.1% vs ⤵️1.1% ✅ ( ⤵️23 vs ⤵️12 mmol/mol) 🔸Wt ⤵️ 9.0kg vs ⤴️ 3.2kg ✅ ⚠️ side effects in tirzepatide up to: 🤢26% 💩15% 🤮13% 🩸Hypo events 0.4 vs 4.4 events/y
349K
GoggleDocs
@GoggleDocs
Mar 14, 2025
Albuminuria: The CKM biomarker we’re overlooking❗️ 💡The best risk stratifying biomarker 🔹 Even UACR <3.4 mg/mmol = ⤴️ #CVD, #CKD & mortality risk 🔸 Signals early endothelial dysfunction across HTN, #T2D, #HF & #MASLD 🔹 Yet 💧screening rates low, esp. in primary care 🔸
24K
GoggleDocs
@GoggleDocs
Aug 8, 2023
#MedTwitter ‼️Breaking News‼️ Semaglutide 2.4mg (#wegovy) ⤵️ 3-point MACE by 20% Top line results only of SELECT trial in #obesity 👉First #weightloss treatment shown to ⤵️ major cardiovascular events ❓driven by ⤵️stroke Full results to come… 🔗 novonordisk.com/news-and-media…
209K
GoggleDocs
@GoggleDocs
Mar 16, 2022
EMPA-KIDNEY trial stopped early due to clear positive efficacy 👏🏽👏🏽 prnewswire.com/news-releases/… reminder of the baseline characteristics 👇🏽
GoggleDocs
@GoggleDocs
Jun 26, 2023
Trial alert ‼️ Oral semaglutide 25mg and 50mg #ADA2023 Obesity 👉 OASIS1 T2DM 👉 PIONEER PLUS 🔹Strong weight loss in obesity (not bad in T2DM) 15-17% (& 8-9%) 🔸Strong ⬇️ Hba1c (2.2%) in T2D 🔹High level GI SE 🤢 but decently tolerated 🔸Talking point 👉 adverse events -
26K
GoggleDocs
@GoggleDocs
Apr 24, 2024
🚨 #Tweetorial alert🚨 1) Welcome to a📷 #tweetorial by the @GoggleDocs team Our topic for today is Novel agents in #CKD in #T2D #MedTwitter #NephTwitter 🙏 to A. Menarini Farmaceutica Internazionale SRL for funding this tweetorial. They have had no input into the content❗️
26K
GoggleDocs
@GoggleDocs
Jan 21, 2025
Finerenone: Do we need another treatment for #CKD in #T2D ❓ 🔹 Reduces CKD progression by 23% & CV events by 14% (FIDELITY analysis). 🔸 Complements RASi & SGLT2i therapies, offering comprehensive cardio-renal protection. ❗️A new pillar in T2D & CKD management, emphasizing
15K
GoggleDocs
@GoggleDocs
Jun 22, 2025
#ADA2025: NA-931 – Oral Quadruple Receptor Agonist 🚀 Targets GLP-1, GIP, glucagon & IGF-1 – aiming for fat loss and lean mass preservation 🔬 Phase 2, 13-week RCT (n=125; BMI ≥30 or ≥27 + comorbidity) 🧍 WL at 13 wks: ⤵️ 11.9% at 150 mg ⤵️ 9.1% at 100 mg vs⤵️ 1.8% (pbo)
24K
GoggleDocs
@GoggleDocs
May 15, 2025
🫀 SELECT: Semaglutide’s Rapid Cardiovascular Benefits (data from #ECO2025) 🔹In adults with obesity & established CVD (no diabetes), semaglutide 2.4 mg weekly: 🔸⤵️ MACE by 41% within 6 months 🔹🕒 First significant benefit seen at day 20 🔸53% ↓ in 💔☠️, 43% ↓ in
19K
GoggleDocs
@GoggleDocs
Nov 11, 2023
‼️SELECT trial - Semaglutide 2.4mg in those with obesity/overweight 🚫diabetes‼️#AHA2023 🔹Inclusion: >45yrs, BMI >27, eASCVD (stroke/MI/symptomatic PAD) 🔸mean age 61.6, BMI 33.3, 72% male 🔹PEP : 3P MACE - achieved! HR 0.80, p<0.001 🔸Just missed CV mortality p0.07…
28K